Statements of Operations-Additional Information

12 Months Ended

Jun. 30, 2022

Statements of Operations-Additional Information

Disaggregated Revenue, Deferred Revenue and Customer Payment Terms

Disaggregated revenue, deferred revenue and customer payment terms

We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. The products help prevent, control and treat diseases, enhance nutrition to help improve animal health and well-being, and contribute to balanced mineral nutrition. The animal health and mineral nutrition products are sold directly to integrated poultry, swine and cattle integrators and through animal feed manufacturers, wholesalers and distributors. The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused in regions where the majority of livestock production is consolidated in large commercial farms.

We have a diversified portfolio of products that are classified within our three business segments — Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team.

Animal Health

The Animal Health business develops, manufactures and markets products in three main categories:

● MFAs and Other: MFAs and other products primarily consist of concentrated medicated products that are administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products.

● Nutritional Specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health. We are also a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers.

● Vaccines: Our vaccines are primarily focused on preventing diseases in poultry and swine. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and autogenous vaccine products and produce and market adjuvants to vaccine manufacturers. We have developed and market an innovative and proprietary delivery platform for vaccines.

Mineral Nutrition

The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their animals’ diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine and beef and dairy cattle.

Performance Products

The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States.

The following tables present our revenues disaggregated by major product category and geographic region:

Net Sales by Product Type

For the Year Ended June 30	2022		2021		2020
Animal Health
MFAs and other	$	361,538	$	330,017	$	322,300
Nutritional specialties		157,196		142,760		129,264
Vaccines		88,321		72,939		75,340
Total Animal Health	$	607,055	$	545,716	$	526,904
Mineral Nutrition		259,512		220,560		214,412
Performance Products		75,694		67,074		59,038
Total	$	942,261	$	833,350	$	800,354

Net Sales by Region

For the Year Ended June 30	2022		2021		2020
United States	$	561,803	$	494,889	$	471,938
Latin America and Canada		191,047		166,325		158,939
Europe, Middle East and Africa		122,480		114,131		112,179
Asia Pacific		66,931		58,005		57,298
Total	$	942,261	$	833,350	$	800,354

Net sales by region are based on country of destination.

Deferred revenue was $2,051 and $3,674 as of June 30, 2022 and June 30, 2021, respectively. Accrued expenses and other current liabilities included $822 and $1,560 of the total deferred revenue as of June 30, 2022 and 2021, respectively. The deferred revenue resulted primarily from certain customer arrangements, including technology licensing fees and discounts on future product sales. The transaction price associated with our deferred revenue arrangements is generally based on the stand-alone sales prices of the individual products or services.

Our customer payment terms generally range from 30 to 120 days globally and do not include any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized.

Additional Information

Additional Information

For the Year Ended June 30	2022		2021		2020
Interest expense, net
Term loan	$	8,962	$	7,951	$	7,751
Revolving credit facility		2,956		3,649		5,317
Amortization of debt issuance costs		590		833		882
Refinancing expense		—		1,020		—
Other		183		265		663
Interest expense		12,691		13,718		14,613
Interest income		(816)		(838)		(1,757)
	$	11,875	$	12,880	$	12,856

For the Year Ended June 30	2022		2021		2020
Depreciation and amortization
Depreciation of property, plant and equipment	$	23,781	$	23,165	$	23,250
Amortization of intangible assets		8,924		8,715		8,869
Amortization of other assets		—		5		222
	$	32,705	$	31,885	$	32,341

Depreciation of property, plant and equipment includes amortization of capitalized software costs of $1,047, $1,254 and $1,038 during 2022, 2021 and 2020, respectively.

Future amortization of intangible assets as of June 30, 2022, is expected to be:

For the Year Ended June 30
2023	$	9,614
2024		9,375
2025		7,769
2026		6,805
2027		6,556
Thereafter		23,742
Total	$	63,861

For the Year Ended June 30	2022		2021		2020
Research and development expense	$	20,832	$	17,759	$	13,738